Analyst: Price cap on insulin is unlikely to affect drugmakers
The consequences of a new bill capping users’ out-of-pocket insulin expenses in the US will be insignificant for insulin makers including Novo Nordisk, says an analyst.
by marketwire, translated by daniel pedersen
Although US lawmakers took one step closer to securing more affordable insulin for people with diabetes in the US, it’ll be of little consequence for the companies supplying the drugs, including Novo Nordisk, Eli Lilly and Sanofi, assesses Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US House of Representatives passes bill to cap insulin price
For subscribers
